YYB-101 is under clinical development by Yooyoung Pharm and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase II drugs for Metastatic Colorectal Cancer have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YYB-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YYB-101 overview

YYB-101 (NOV-110501) is under development for the treatment of solid tumors including glioblastoma multiforme (GBM), non-small cell lung cancer, hepatocellular carcinoma, ovarian cancer, melanoma, metastatic colorectal cancer, leiomyosarcoma and pancreatic cancer. The drug candidate is a new molecular entity humanized IgG4 antibody and targets HGF (Hepatocyte Growth Factor). The protein belongs to the plasminogen subfamily of S1 peptidases but has no detectable protease activity.

Yooyoung Pharm overview

Yooyoung Pharm (Yooyoung) is a manufacturer and distributor of finished pharmaceutical products. The company offers ethical drugs products such as antiarthritic agents, antibiotics, anti infammatory enzymes, antifungal and antiviral agents, hepatic protectors, antihistamines, antipsychotics, antidepressants, cardiovascular agents, antiplatelet agents, hemostatics, and others. It offers products in the dosage forms of oral solid, injection, tablet, vial, capsule, ampoule, granule, and pre-filled syringe. Yooyoung’s products are used in the treatment of amyotrophic lateral sclerosis, allergic rhinitis, autoimmune diseases, chronic pain, hyperlipidemia, osteo arthritis, peptic ilcer, hyperlipidemia and various cancers. The company exports its products across Japan, Vietnam, Philippines, Thailand, HongKong, and Russia. Yooyoung is headquartered in Seoul, South Korea.

For a complete picture of YYB-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.